Overview
Liquid biopsy is a noninvasive diagnostic approach that detects circulating biomarkers released from tumors into body fluids. It represents a major advancement in cancer screening, diagnosis, and monitoring by allowing real-time assessment of tumor dynamics without the need for tissue biopsy. Liquid biopsy primarily identifies circulating tumor cells, circulating tumor DNA, and other tumor-derived components shed from primary or metastatic lesions. With advances in next-generation sequencing, liquid biopsy has emerged as a powerful tool for early cancer detection and personalized oncology care.
Symptoms
Liquid biopsy itself is not associated with symptoms and is performed to evaluate underlying malignancies. It is commonly used in patients with suspected cancer, known malignancy under treatment, or those being monitored for recurrence. Symptoms prompting evaluation may include unexplained weight loss, fatigue, persistent pain, abnormal imaging findings, or clinical suspicion of disease progression. In many cases, liquid biopsy is used even when patients are asymptomatic to detect minimal residual disease.
Causes
Liquid biopsy detects tumor-derived material released into circulation as a result of tumor cell turnover, apoptosis, necrosis, or active secretion. These include circulating tumor cells, cell-free tumor DNA, RNA fragments, and exosomes carrying molecular information. Genetic alterations such as point mutations, copy number variations, chromosomal rearrangements, and epigenetic changes can be identified through these biomarkers. The presence of these markers reflects tumor burden, molecular profile, and treatment response.
Risk Factors
Risk factors necessitating liquid biopsy include known malignancy, high risk of cancer recurrence, advanced-stage disease, and tumors that are difficult to access by tissue biopsy. Patients undergoing targeted therapy or immunotherapy benefit from molecular monitoring using liquid biopsy. Tumor heterogeneity, low biomarker levels, and prior treatment may affect detection sensitivity. Technical factors such as sample handling, storage, and analytical methods also influence accuracy.
Prevention
While cancer itself cannot be prevented through liquid biopsy, early detection and monitoring significantly reduce morbidity and improve outcomes. Use of liquid biopsy allows timely identification of treatment resistance, disease progression, and relapse before clinical symptoms appear. Proper sample collection, standardized processing, and integration with clinical findings enhance reliability. Liquid biopsy complements conventional diagnostic methods and supports precision medicine by enabling early intervention and personalized treatment strategies.
